▶️ #Fluorescence Quenching of Xanthene #Dyes during Amide Bond Formation Using DMTMM 👥 Kristen N. Patterson, Misael A. Romero-Reyes, and Jennifer M. Heemstra go.acs.org/2jc Jen Heemstra Heemstra Lab WashU Chem Emory Chemistry

Great work Kristen Patterson !

Congratulations Dr. Dentmon on an an exceptional thesis defense delivery today and a well-earned doctorate!

From Liotta group member Dr. Luke Hodson - “I had such a great time showcasing Agrithera’s cannabinoid prodrug technology at the #cghisummit on Tuesday. Special congrats to Dr. Dennis Liotta, for being awarded runner up in the pitch rounds!” Congratulations @EricJMillerLab Jeff🧢

Samuel Candler Dobbs Professor of Chemistry Liotta Research Group, recognized as one of the premier discoverers of novel therapeutics in the U.S., is presenting a talk titled “Novel Therapeutics for Treating Cancers, Neurological Disorders & Viral Diseases” on 10/28. ow.ly/yoZJ50LjbxO

Join us in welcoming The Graduate Center alumnus and Samuel Candler Dobbs Professor of Chemistry Liotta Research Group, on Oct. 28 for a talk about novel therapeutics for treating cancers, neurological disorders and viral diseases. GC Sciences ow.ly/UbWr50LjfJn

.The Graduate Center alumnus Liotta Research Group's innovations have resulted in 18 life-saving FDA-approved antiviral therapeutics, including the first-ever combination therapy for HIV/AIDS as a once-daily pill. Tune into his talk on Oct. 28 to learn all about his research! ow.ly/AoTO50LjsxY

TFV is the cornerstone NtRTI in many combination antiretroviral therapies prescribed to patients living with HIV. This paper describes two novel TFV prodrugs with improved metabolic stability, half-life, and pharmacokinetic traits: pubs.acs.org/doi/10.1021/ac…

"Try to be an intellectual sponge." Alumnus Dennis Liotta (@liottalab), whose work transformed HIV treatment, shares his advice for today’s @gc_cuny Ph.D. students gc.cuny.edu/news/alumnus-d… CUNY ASRC CUNYChemistryPhD @GCSciences @emorychem

Our very own @HGold26 presenting her work at the Winship Cancer Institute of Emory University Winship Scientific Symposium yesterday! 🧪🧬🧫

CXCR4 antagonist TIQ15 was rationally modified to improve drug-like properties. Introducing a nitrogen atom in the tetrahydroisoquinoline ring reduces inhibition of the CYP2D6 enzyme while retaining CXCR4 potency. pubs.acs.org/doi/pdf/10.102…

Happy Holidays from our Liotta Family to yours! So much fun at our annual Holiday potluck!

A series of NMDA receptor subunit 2B-selective inhibitors show enhanced activity at a more acidic extracellular pH relative to physiologic pH. This property renders compounds more effective at synapses responding to a high frequency of action potentials. jpet.aspetjournals.org/content/379/1/…

Quick magic break 👍

Nucleoside- and nucleotide-based therapies including Tenofovir (TFV) are commonly given to patients as prodrugs to maximize bioavailability. We designed three series of novel TFV prodrugs shown to optimize antiviral activity and metabolic stability: frontiersin.org/articles/10.33…

Congrats to Emory's Dennis Liotta for his great work that is highlighted here.

As we welcome students back to school for the fall semester, our scholars offer advice to thrive in graduate school ow.ly/oOCc50PAT8K Liotta Research Group

Congrats to #EmoryCFAR Member, Dennis Liotta (Liotta Research Group) who was honored at the White House for innovation in #HIV treatment! Dr. Liotta was one of five to receive an inaugural Bayh-Dole Coalition American Innovator Award. Learn more via Emory University News: news.emory.edu/stories/2023/0…

.Bayh-Dole Coalition American Innovator Award recipient and Emory University professor Dr. Liotta Research Group, best known for his groundbreaking discoveries in HIV treatment, was featured in an article by #eGreenews! Read it here ⤵️ buff.ly/3F0y0pV

#SEMSS2023 is off and running, with a great keynote from Liotta Research Group, heading into breakout sessions and posters this afternoon! Thanks to the SEMSS organizing committees for a great start to the weekend!